New published findings by Dr. Cote’s group examining continued smoking among African American cancer survivors in the Detroit Research on Cancer Survivors Study
Dr. Michele Cote’s (NTRD member) research group has just published a new article, first authored by Carly Malburg, that examines factors associated with continued smoking among African American cancer survivors in Detroit. This exciting new study highlights the need for effective smoking cessation among a treatment population that is both vulnerable to the harmful effects of smoking, and who may also be receptive to personalized smoking cessation interventions. Details of this important new study are provided below…
Malburg, C.M., Fucinari, J., Ruterbusch, J.J., Ledgerwood, D.M., Beebe-Dimmer, J.L., Schwartz, A.G., & Cote, M.L. (in press). Continued smoking in African American cancer survivors: The Detroit Research on Cancer Survivors Cohort. Cancer Medicine.
Tobacco cessation among those recently diagnosed with cancer is important to improve their prognosis, yet, many cancer survivors continue to smoke. The epidemiology of tobacco use differs by race and ethnicity, and limited cessation research has been conducted in African American (AA) populations. Here, we assess demographic and clinical variables associated with continued smoking in AAs after a cancer diagnosis. The Detroit Research on Cancer Survivors study is a cohort comprised of AA cancer survivors with breast, prostate, lung, and colorectal cancers. Detroit Research on Cancer Survivors data were utilized from survivors who completed their baseline survey within 18 months of cancer diagnosis (n = 1145); 18% (n = 356) reported smoking at the time of cancer diagnosis, and 57% of these (n = 203) continued to smoke after their diagnosis. Logistic regression models were used to assess factors associated with continued smoking. Living with a smoker (odds ratio [OR] = 2.78, 95% confidence interval [CI]: 1.64, 4.70), higher cumulative years of smoking (OR = 1.03, 95% CI: 1.01, 1.05, for each year), and a prostate cancer diagnosis (OR = 7.35, 95% CI: 3.89, 13.89) were all associated with increased odds of continued smoking. Survivors with higher social well‐being scores (measured by the Functional Assessment of Cancer Therapy, a quality of life assessment) were more likely to quit smoking after diagnosis (OR = 0.96, 95% CI: 0.93, 1.00). These findings highlight the continued need for personalized cessation strategies to be incorporated into treatment plans for cancer survivors.
This work was supported by the National Cancer Institute of the National Institutes of Health (U01 CA199240 and P30 CA022453), the Barbara Ann Karmanos Cancer Institute, and the Metropolitan Detroit Cancer Surveillance System (Detroit Surveillance, Epidemiology, and End Results Cancer Registry contract HHSN‐261201300011I).